Skip to main content

Unable to load price data. Sorry.


Chelsea Therapeutics International Ltd. (NASDAQ:CHTP.DL)

CAPS Rating: No stars

A development stage pharmaceutical company that seeks to acquire and develop innovative products for the treatment of a variety of human diseases.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CHTP.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

drunknmonkey213 (< 20)
Submitted February 26, 2014

After it's main drug Northera was approved mid-February, the stock jumped higher, though only to a similar high as when an FDA advisory panel voted overwhelmingly to approve Northera one month earlier (over $6 after-hours). Shorts and critics believe… More

zzlangerhans (99.75)
Submitted June 07, 2013

The Northera soap opera continues as Chelsea plans to resubmit the NDA in late Q2 or early Q3, and the stock is rising presumably on the basis of Chelsea's position that they will be allowed to perform a confirmatory phase III trial subsequent to… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about CHTP.DL.

No one has written a Pitch for CHTP.DL stock yet. Tell us why you think CHTP.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in CHTP.DL.

No players have picked CHTP.DL yet. Tell us why you think CHTP.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CHTP.DL.